TCG Lifesciences and Endo enter discovery alliance
This article was originally published in Scrip
Executive Summary
TCG Lifesciences, a research services and informatics company, is collaborating with Endo Pharmaceuticals to discover novel small-molecule drug candidates for the treatment of pain. The tie-up will focus on an integrated approach involving medicinal chemistry, biology and animal pharmacology capabilities of TCG's discovery research arm, Chembiotek. Endo will have full ownership of the compounds developed under the collaboration as well as exclusive global rights. It will also finance all subsequent drug development and commercialisation activities, provide research funding and make milestone payments to TCG. TCG is based in India and is part of The Chatterjee Group, an investment conglomerate headquartered in New York.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.